DE60008293D1 - Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung - Google Patents

Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung

Info

Publication number
DE60008293D1
DE60008293D1 DE60008293T DE60008293T DE60008293D1 DE 60008293 D1 DE60008293 D1 DE 60008293D1 DE 60008293 T DE60008293 T DE 60008293T DE 60008293 T DE60008293 T DE 60008293T DE 60008293 D1 DE60008293 D1 DE 60008293D1
Authority
DE
Germany
Prior art keywords
composition containing
donor
pharmaceutical composition
therapeutic use
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60008293T
Other languages
English (en)
Other versions
DE60008293T2 (de
Inventor
Maurice Israel
La Porte Sabine De
Philippe Fossier
Emmanuel Chaubourt
Gerard Baux
Christiane Leprince
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60008293D1 publication Critical patent/DE60008293D1/de
Publication of DE60008293T2 publication Critical patent/DE60008293T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE2000608293 1999-06-11 2000-06-09 Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung Expired - Fee Related DE60008293T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9907442A FR2794647A1 (fr) 1999-06-11 1999-06-11 Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
FR9907442 1999-06-11
PCT/FR2000/001612 WO2000076451A2 (fr) 1999-06-11 2000-06-09 Composition pharmaceutique comprenant du no un compose donneur de no, ou inducteur de la formation de no et son utilisation en therapie

Publications (2)

Publication Number Publication Date
DE60008293D1 true DE60008293D1 (de) 2004-03-18
DE60008293T2 DE60008293T2 (de) 2005-01-13

Family

ID=9546698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000608293 Expired - Fee Related DE60008293T2 (de) 1999-06-11 2000-06-09 Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung

Country Status (12)

Country Link
US (1) US6872751B2 (de)
EP (1) EP1231908B1 (de)
JP (1) JP2003506320A (de)
AT (1) ATE259223T1 (de)
AU (1) AU776692B2 (de)
CA (1) CA2376302A1 (de)
DE (1) DE60008293T2 (de)
DK (1) DK1231908T3 (de)
ES (1) ES2213032T3 (de)
FR (1) FR2794647A1 (de)
PT (1) PT1231908E (de)
WO (1) WO2000076451A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
EP1596854A4 (de) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase
US20070191377A1 (en) * 2004-03-31 2007-08-16 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
WO2007020917A1 (ja) * 2005-08-18 2007-02-22 The University Of Tokushima ユートロフィン産生の増強持続剤とこれを用いる加工食品
CN101378739B (zh) * 2006-02-03 2014-06-04 尼科克斯公司 药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用
US9452117B2 (en) * 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
EP2837390A1 (de) * 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Kombiniertes pharmazeutisches Paräparat zur Verwendung bei der Behandlung von Nerven-Muskel-Störungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704173B2 (en) * 1993-11-02 1999-04-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
US6153186A (en) * 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
WO1997033173A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
DE29709820U1 (de) * 1996-06-10 1997-07-31 Nutrend S R O Lebensmittel-Spezialzusatz
EP0929538B1 (de) * 1996-09-27 2004-11-24 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES O2-arylate oder o2 glycosyiate 1-substituierte diazen-1-ium-1,2 diolate und o2-substituierte 1 (2-carboxylate) pyrolidin-1-yl diazen-1-ium-1,2-diolate
US6110930A (en) * 1997-04-10 2000-08-29 Ono Pharmaceutical Co., Ltd. Condensed piperidine compound
US6232336B1 (en) * 1997-07-03 2001-05-15 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
WO2000053191A2 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Modulation of skeletal muscle precursor cell activation
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Also Published As

Publication number Publication date
DK1231908T3 (da) 2004-06-14
WO2000076451A3 (fr) 2002-06-20
EP1231908B1 (de) 2004-02-11
CA2376302A1 (fr) 2000-12-21
JP2003506320A (ja) 2003-02-18
US20020164383A1 (en) 2002-11-07
US6872751B2 (en) 2005-03-29
EP1231908A2 (de) 2002-08-21
FR2794647A1 (fr) 2000-12-15
AU776692B2 (en) 2004-09-16
ES2213032T3 (es) 2004-08-16
ATE259223T1 (de) 2004-02-15
DE60008293T2 (de) 2005-01-13
WO2000076451A2 (fr) 2000-12-21
AU6447300A (en) 2001-01-02
PT1231908E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
EP1633368A4 (de) Schäumende pharmazeutische zusammensetzungen und verfahren zur behandlung einer erkrankung
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
HUP0203249A2 (hu) Dipiridamol és mopidamol alkalmazása fibrinfüggő mikrokeringési rendellenességek kezelésére és megelőzésére szolgáló gyógyszer készítésére
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
DE60008293D1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria
GB9917290D0 (en) Pharmaceutical composition
EP0880967A3 (de) Nephroprotektive Arzneimittel
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee